腎絲球腎炎市場規模、佔有率和成長分析：按疾病亞型、治療方法、給藥途徑、最終用戶和地區分類－2026-2033年產業預測

2024 年全球腎絲球腎炎市值為 110.6 億美元，預計到 2025 年將成長至 116.5 億美元，到 2033 年將成長至 141.4 億美元，在預測期（2026-2033 年）內複合年成長率為 5.3%。

受自體免疫和腎臟疾病盛行率上升以及先進生物製藥療法日益普及的推動，腎絲球腎炎治療市場正經歷顯著成長。人們對早期診斷重要性的認知不斷提高、保險覆蓋範圍擴大以及精準醫療的進步進一步促進了市場動態。生物製藥、補體抑制劑、免疫抑制劑和先進診斷工具的持續成長是推動這一成長的重要因素。對精準醫療、標靶生物製藥研發以及尿液蛋白質體學和疾病特異性療法的投入正在改善患者的治療效果。然而，高昂的治療費用、發展中國家醫療資源有限、嚴格的法規環境以及長期治療可能帶來的副作用等挑戰，可能會阻礙未來的市場滲透。

全球腎絲球腎炎市場按疾病亞型、治療方法、給藥途徑、最終用戶和地區進行細分。依疾病亞型分類，市場分為IgA腎臟病、膜性腎臟病、局部節段性腎絲球硬化症和膜增生性腎絲球腎炎。依治療方法分類，市場分為糖皮質激素、免疫抑制劑、非免疫抑制療法、補體抑制劑。依給藥途徑分類，市場分為口服和注射劑型。按最終用戶分類，市場分為醫院、腎臟科診所和居家醫療服務。依地區分類，市場分為北美、歐洲、亞太、拉丁美洲以及中東和非洲。

全球腎絲球腎炎市場成長要素

全球腎絲球腎炎市場成長的主要驅動力在於大眾和醫療專業人員對該疾病症狀的認知度不斷提高。這種認知的提升使得早期診斷和更快啟動治療成為可能。這得益於衛生組織和患者權益倡導團體所進行的宣傳活動，這些活動提高了公眾對該疾病進展的認知。這些努力鼓勵醫療專業人員實施篩檢項目，最終導致診斷率上升。因此，不僅現有療法的需求增加，開發創新療法的機會也在擴大，進一步拓展了腎絲球腎炎市場。

全球腎絲球腎炎市場的限制因素

全球腎絲球腎炎市場面臨諸多限制因素，其中之一便是新藥研發成本高。複雜的生產流程和大規模臨床試驗推高了藥品價格，使得病患難以獲得創新療法，尤其是在健保報銷體係不完善的地區。因此，醫療服務提供者往往優先考慮價格較低的替代療法，導致新療法的普及率較低。經濟障礙進一步阻礙了保險公司對這些昂貴藥物的投資，導致這些藥物被延遲納入健保範圍。這種情況限制了患者獲得先進治療方案的機會，最終影響患者的治療和療效。

全球腎絲球腎炎市場趨勢

全球腎絲球腎炎市場正經歷一場變革，而精準免疫療法的日益普及正是推動這項變革的主要動力。這一趨勢著重於開發針對疾病潛在病理機制（例如補體活化和細胞激素訊號傳導）的標靶治療。先進分子診斷技術的出現使得患者分層更加精準，從而能夠早期療育並制定更有效的治療策略。這種方法減少了對特異性免疫抑制劑的依賴，並符合以價值為導向的醫療保健實踐，在這種實踐中，醫療保險公司越來越支持那些療效顯著且能改善患者預後的創新治療方案。因此，預計該市場將迎來顯著成長。

目錄

介紹

• 調查目的
• 市場定義和範圍

調查方法

• 研究過程
• 二級資料和一級資料的方法
• 市場規模估算方法

執行摘要

• 全球市場展望
• 市場主要亮點
• 細分市場概覽
• 競爭環境概述

市場動態及展望

• 總體經濟指標
• 促進者和機會
• 抑制因素和挑戰
• 供給面趨勢
• 需求面趨勢
• 波特的分析和影響

關鍵市場分析

• 關鍵成功因素
• 影響市場的因素
• 主要投資機會
• 生態系測繪
• 2025年市場魅力指數
• PESTLE分析
• 監理情勢

全球腎絲球腎炎市場規模：依疾病亞型分類

• IgA腎臟病
• 膜性腎臟病
• 局部性節段性腎絲球硬化症
• 膜增生性腎絲球腎炎

全球腎絲球腎炎市場規模：依治療類型分類

• 皮質類固醇
• 免疫抑制劑
• 非免疫抑制療法
• 補體抑制劑

全球腎絲球腎炎市場規模：依給藥途徑分類

• 口服
• 注射藥物

全球腎絲球腎炎市場規模：依最終用戶分類

• 醫院
• 腎臟病診所
• 居家照護服務

全球腎絲球腎炎市場規模：依地區分類

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲國家
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太國家
• 拉丁美洲
  • 墨西哥
  • 巴西
  • 其他拉丁美洲國家
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲國家

競爭資訊

• 前五大公司對比
• 主要公司2025年的市場定位
• 主要市場公司採取的策略
• 近期市場趨勢
• 企業市場占有率分析，2025 年
• 主要公司的完整公司簡介
  • 公司詳情
  • 產品系列分析
  • 按細分市場進行企業市佔率分析
  • 銷售收入年比比較（2023-2025 年）

主要公司簡介

• Travere Therapeutics Inc
• Biogen Inc
• Achillion Pharmaceuticals Inc
• Anthera Pharmaceuticals Inc
• Cellmid Limited
• ChemoCentryx Inc
• Complexa Inc
• Dimerix Bioscience Pty Ltd
• GlaxoSmithKline plc
• Merck KGaA
• Omeros Corporation
• Pfizer Inc
• Pharmalink AB
• Ra Pharmaceuticals Inc
• Retrophin Inc
• Rigel Pharmaceuticals Inc
• Shire Pharmaceuticals Group
• Visterra Inc
• Novartis AG
• Vertex Pharmaceuticals Inc

結論與建議

Global Glomerulonephritis Market size was valued at USD 11.06 Billion in 2024 and is poised to grow from USD 11.65 Billion in 2025 to USD 14.14 Billion by 2033, growing at a CAGR of 5.3% during the forecast period (2026-2033).

The glomerulonephritis treatment market is experiencing significant growth due to the rising prevalence of autoimmune and kidney diseases, alongside an increasing adoption of advanced biologic therapies. Enhanced awareness of the importance of early diagnosis, improvements in reimbursement coverage, and advancements in precision medicine are further propelling market dynamics. The upward trend in biologics, complement inhibitors, immunosuppressants, and sophisticated diagnostic tools significantly contributes to this growth. Investments in precision medicine and the development of targeted biologic agents, coupled with urinary proteomics and disease-specific therapies, are improving patient outcomes. However, challenges such as high treatment costs, limited access in developing regions, stringent regulatory environments, and potential side effects from long-term therapies may hinder market penetration moving forward.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Glomerulonephritis market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Glomerulonephritis Market Segments Analysis

Global glomerulonephritis market is segmented by disease subtype, treatment type, route of administration, end user, and region. Based on disease subtype, the market is segmented into IgA nephropathy, membranous nephropathy, focal segmental glomerulosclerosis, and membranoproliferative glomerulonephritis. Based on treatment type, the market is segmented into corticosteroids, immunosuppressants, non immunosuppressive therapies, and complement inhibitors. Based on route of administration, the market is segmented into oral and injectable. Based on end user, the market is segmented into hospitals, nephrology clinics, and homecare services. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.

Driver of the Global Glomerulonephritis Market

The global market for glomerulonephritis is significantly driven by heightened awareness among both the public and healthcare professionals about the condition's symptoms. This growing knowledge facilitates earlier diagnosis and prompt initiation of treatment, as health organizations and patient advocacy groups conduct campaigns to educate communities on the disease's progression. Such initiatives encourage health professionals to adopt screening programs, ultimately leading to an increase in diagnosed cases. As a result, there is a growing demand for existing treatment options as well as opportunities for the development of innovative therapies, expanding the overall market landscape for glomerulonephritis.

Restraints in the Global Glomerulonephritis Market

The global glomerulonephritis market faces significant constraints due to the high costs associated with developing new medications. The intricate production processes and extensive clinical trials contribute to elevated pricing, creating challenges in patient access to innovative treatments, particularly in regions where reimbursement policies are lacking. Consequently, healthcare providers may favor more affordable alternatives, leading to reduced adoption rates for newer therapies. Economic barriers further hinder payers from investing in these costly drugs, resulting in delays in their inclusion on formularies. This situation restricts the availability of advanced treatment options, ultimately impacting patient care and outcomes.

Market Trends of the Global Glomerulonephritis Market

The Global Glomerulonephritis market is experiencing a transformative shift with the rising adoption of precision immunotherapy. This trend focuses on developing targeted therapeutics tailored to the underlying pathological mechanisms of the disease, such as complement activation and cytokine signaling. The emergence of advanced molecular diagnostics has enabled better patient stratification, allowing for early intervention and more effective management strategies. This approach reduces reliance on conventional nonspecific immunosuppressants and aligns with the practice of value-based medicine, where healthcare payers are increasingly supportive of innovative treatment options that demonstrate clear efficacy and improved patient outcomes. As a result, the market is poised for significant growth.

Table of Contents

Introduction

• Objectives of the Study
• Market Definition & Scope

Research Methodology

• Research Process
• Secondary & Primary Data Methods
• Market Size Estimation Methods

Executive Summary

• Global Market Outlook
• Key Market Highlights
• Segmental Overview
• Competition Overview

Market Dynamics & Outlook

• Macro-Economic Indicators
• Drivers & Opportunities
• Restraints & Challenges
• Supply Side Trends
• Demand Side Trends
• Porters Analysis & Impact
  • Competitive Rivalry
  • Threat of Substitute
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Market Insights

• Key Success Factors
• Market Impacting Factors
• Top Investment Pockets
• Ecosystem Mapping
• Market Attractiveness Index 2025
• PESTEL Analysis
• Regulatory Landscape

Global Glomerulonephritis Market Size by Disease Subtype & CAGR (2026-2033)

• Market Overview
• IgA Nephropathy
• Membranous Nephropathy
• Focal Segmental Glomerulosclerosis
• Membranoproliferative Glomerulonephritis

Global Glomerulonephritis Market Size by Treatment Type & CAGR (2026-2033)

• Market Overview
• Corticosteroids
• Immunosuppressants
• Non Immunosuppressive Therapies
• Complement Inhibitors

Global Glomerulonephritis Market Size by Route of Administration & CAGR (2026-2033)

• Market Overview
• Oral
• Injectable

Global Glomerulonephritis Market Size by End User & CAGR (2026-2033)

• Market Overview
• Hospitals
• Nephrology Clinics
• Homecare Services

Global Glomerulonephritis Market Size & CAGR (2026-2033)

• North America (Disease Subtype, Treatment Type, Route of Administration, End User)
  • US
  • Canada
• Europe (Disease Subtype, Treatment Type, Route of Administration, End User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Disease Subtype, Treatment Type, Route of Administration, End User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Disease Subtype, Treatment Type, Route of Administration, End User)
  • Mexico
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Disease Subtype, Treatment Type, Route of Administration, End User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• Travere Therapeutics Inc
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Biogen Inc
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Achillion Pharmaceuticals Inc
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Anthera Pharmaceuticals Inc
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cellmid Limited
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• ChemoCentryx Inc
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Complexa Inc
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Dimerix Bioscience Pty Ltd
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GlaxoSmithKline plc
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck KGaA
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Omeros Corporation
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pharmalink AB
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Ra Pharmaceuticals Inc
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Retrophin Inc
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Rigel Pharmaceuticals Inc
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Shire Pharmaceuticals Group
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Visterra Inc
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Vertex Pharmaceuticals Inc
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations